Biogen Q3 FY2026 results
$253.40+1.17%
Biogen reported revenue of $2.80 billion, up 10.6% from a year earlier, net income of −$20.6 million and diluted earnings per share of −$0.14 against $3.17 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 28 Oct 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $2.80B | $2.53B | +10.6% |
| Gross profit | $2.06B | $1.86B | +10.5% |
| Gross margin | 73.3% | 73.4% | −0.1 pts |
| Operating income | −$9.00M | $557.3M | — |
| Operating margin | −0.3% | 22.0% | −22.3 pts |
| Net income | −$20.60M | $466.5M | — |
| Diluted EPS | −$0.14 | $3.17 | — |
| Operating cash flow | $640.8M | $1.27B | −49.6% |
| Capital expenditure | $40.40M | $46.20M | −12.6% |
| Free cash flow | $600.4M | $1.23B | −51.0% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Product revenue, net revenue | $2.1B | up 13.1% |
| MS Product Revenues | $919.3M | down 13.4% |
| Rare Disease Product Revenue | $676.3M | up 26.8% |
| Revenue from anti-CD20 therapeutic programs revenue | $497.3M | up 0.7% |
| SPINRAZA revenue | $460.6M | up 23.2% |
| TYSABRI revenue | $437.1M | up 1.2% |
| Royalty Attributed To OCREVUS revenue | $369.9M | down 4.3% |
| Fumarate revenue | $274.0M | down 28.4% |
| Specialized Immunology revenue | $242.8M | — |
| Interferon revenue | $208.2M | down 15.7% |
| VUMERITY revenue | $192.0M | down 10.5% |
| SYFOVRE revenue | $191.3M | — |
| SKYCLARYS revenue | $178.2M | up 34.1% |
| Biosimilars revenue | $165.9M | down 15.7% |
| AVONEX revenue | $156.6M | down 16.9% |
| Contract manufacturing, royalty and other revenue | $149.7M | down 1.0% |
| Contract manufacturing revenue | $135.9M | down 4.0% |
| BENEPALI revenue | $117.3M | down 3.8% |
| ZURZUVAE revenue | $84.4M | up 52.6% |
| TECFIDERA revenue | $82.0M | down 51.2% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $2.80B | +10.6% | −$0.14 |
| Q2 FY2026 | 30 Jun 2026 | $2.74B | +3.4% | $0.66 |
| Q1 FY2026 | 31 Mar 2026 | $2.48B | +1.9% | $2.15 |
| Q4 FY2025 | 31 Dec 2025 | $2.28B | −7.1% | −$0.33 |
| Q3 FY2025 | 30 Sep 2025 | $2.53B | +2.8% | $3.17 |
| Q2 FY2025 | 30 Jun 2025 | $2.65B | +7.3% | $4.33 |
| Q1 FY2025 | 31 Mar 2025 | $2.43B | +6.1% | $1.64 |
| Q4 FY2024 | 31 Dec 2024 | $2.45B | +2.9% | $1.83 |
More on Biogen: financial statements · revenue · earnings per share
BIIB's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
